Shuchi S Pandya
Overview
Explore the profile of Shuchi S Pandya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1959
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan B, Abou-Alfa G, Zhu A, Pandya S, Jia H, Yin F, et al.
Cancer Chemother Pharmacol
. 2024 Jan;
93(5):471-479.
PMID: 38278871
Purpose: Report pharmacokinetic (PK)/pharmacodynamic (PD) findings from the phase III ClarIDHy study and any association between PK/PD parameters and treatment outcomes in this population. Methods: Patients with mutant isocitrate dehydrogenase...
2.
Mellinghoff I, Lu M, Wen P, Taylor J, Maher E, Arrillaga-Romany I, et al.
Nat Med
. 2023 Jul;
30(1):302.
PMID: 37400643
No abstract available.
3.
DiNardo C, de Botton S, Pollyea D, Stone R, Altman J, Fathi A, et al.
Am J Hematol
. 2023 Jun;
98(9):E233-E236.
PMID: 37354069
No abstract available.
4.
Mellinghoff I, van den Bent M, Blumenthal D, Touat M, Peters K, Clarke J, et al.
N Engl J Med
. 2023 Jun;
389(7):589-601.
PMID: 37272516
Background: Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed...
5.
Mellinghoff I, Lu M, Wen P, Taylor J, Maher E, Arrillaga-Romany I, et al.
Nat Med
. 2023 Feb;
29(3):615-622.
PMID: 36823302
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase 1 trial to...
6.
Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al.
N Engl J Med
. 2022 Apr;
386(16):1519-1531.
PMID: 35443108
Background: The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly...
7.
Ellingson B, Kim G, Brown M, Lee J, Salamon N, Steelman L, et al.
Neuro Oncol
. 2021 Nov;
24(5):770-778.
PMID: 34751786
Background: Since IDH-mutant (mIDH) low-grade gliomas (LGGs) progress slowly and have a relatively long survival, there is a significant need for earlier measurements of clinical benefit. Guidance using the LGG...
8.
Zhu A, Macarulla T, Javle M, Kelley R, Lubner S, Adeva J, et al.
JAMA Oncol
. 2021 Sep;
7(11):1669-1677.
PMID: 34554208
Importance: Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free survival as determined by central review was significantly...
9.
Mellinghoff I, Penas-Prado M, Peters K, Burris 3rd H, Maher E, Janku F, et al.
Clin Cancer Res
. 2021 Jun;
27(16):4491-4499.
PMID: 34078652
Purpose: Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy is associated with short- and long-term toxicity. Progression to higher tumor grade is associated with contrast enhancement on MRI....
10.
Aguado-Fraile E, Tassinari A, Ishii Y, Sigel C, Lowery M, Goyal L, et al.
Future Oncol
. 2021 Mar;
17(16):2057-2074.
PMID: 33709779
mutations occur in approximately 13% of intrahepatic cholangiocarcinomas (IHCCs). The oral, targeted, mutant IDH1 (mIDH1) inhibitor ivosidenib (AG-120) suppresses production of the oncometabolite D-2-hydroxyglutarate, promoting disease stabilization and improved progression-free...